The insulin-like growth factor I generation test

Resistance to growth hormone with aging and estrogen replacement therapy

Steven Lieberman, A. M. Mitchell, R. Marcus, R. L. Hintz, A. R. Hoffman

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Circulating IGF-I is primarily regulated by growth hormone, but other factors such as nutritional status may also influence IGF-I secretion. The effects of age, gender, and estrogen replacement on responsiveness of serum IGF-I to GH administration have not been directly studied. The high affinity circulating GH-binding protein (GHBP) has the same structure as the extracellular domain of the GH receptor and may reflect the sensitivity to GH in humans. To examine these issues, we employed an IGF-I generation test in which a single dose of GH (0.1 mg/kg SQ) was administered to 31 healthy adults comprising five groups: young (20-29 years) males (YM), young females in the follicular phase of the menstrual cycle (YF), older (60-69 years) males (OM), older females not on estrogen replacement (OFN), and older females on oral estrogen replacement (OFE). Blood was sampled for IGF-I and GHBP over 72 hours following GH administration. OM had lower peak IGF-I levels (323 ± 38 vs. 497 ± 85 μg/l, p = 0.0015) and a lower IGF-I response to GH (ΔIGF-I: 187 ± 33 vs. 293 ± 57 μg/l, p = 0.0085) than YM. OFE had lower basal IGF-I (63 ± 11 vs. 133 ± 19 μg/1, p= 0.0046), peak IGF-I (174 ± 28 vs. 400 ± 40 μg/l, p = 0.0015), and ΔIGF-I (111 ± 21 vs. 268 ± 27 μg/l, p = 0.0085) than OFN. IGFBP-3 levels were unchanged 24 hours after GH administration. GHBP levels fell transiently in all subjects by an average of 22.9 ± 1.7%, with no differences among the groups. There was no correlation between IGF-I response and basal GHBP levels (r = 0.169, p > 0.35). We conclude that (1) a single subcutaneous dose of GH is a convenient and direct method for assessing responsiveness to GH, (2) aging in males and oral estrogen therapy in postmenopausal women are accompanied by resistance to GH, (3) GH administration acutely lowers circulating GHBP, and (4) the level of circulating GHBP does not predict the IGF-I response to GH.

Original languageEnglish (US)
Pages (from-to)229-233
Number of pages5
JournalHormone and Metabolic Research
Volume26
Issue number5
StatePublished - 1994
Externally publishedYes

Fingerprint

Estrogen Replacement Therapy
Insulin-Like Growth Factor I
Growth Hormone
Estrogens
Aging of materials
Insulin-Like Growth Factor Binding Protein 3
Follicular Phase
Nutritional Status
somatotropin-binding protein
Blood

Keywords

  • aging
  • estrogen
  • growth hormone
  • growth hormone-binding protein
  • IGF-binding protein 3
  • insulin-like growth factor I

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

The insulin-like growth factor I generation test : Resistance to growth hormone with aging and estrogen replacement therapy. / Lieberman, Steven; Mitchell, A. M.; Marcus, R.; Hintz, R. L.; Hoffman, A. R.

In: Hormone and Metabolic Research, Vol. 26, No. 5, 1994, p. 229-233.

Research output: Contribution to journalArticle

@article{066b63ef6b144efcb65cdbb18be050ee,
title = "The insulin-like growth factor I generation test: Resistance to growth hormone with aging and estrogen replacement therapy",
abstract = "Circulating IGF-I is primarily regulated by growth hormone, but other factors such as nutritional status may also influence IGF-I secretion. The effects of age, gender, and estrogen replacement on responsiveness of serum IGF-I to GH administration have not been directly studied. The high affinity circulating GH-binding protein (GHBP) has the same structure as the extracellular domain of the GH receptor and may reflect the sensitivity to GH in humans. To examine these issues, we employed an IGF-I generation test in which a single dose of GH (0.1 mg/kg SQ) was administered to 31 healthy adults comprising five groups: young (20-29 years) males (YM), young females in the follicular phase of the menstrual cycle (YF), older (60-69 years) males (OM), older females not on estrogen replacement (OFN), and older females on oral estrogen replacement (OFE). Blood was sampled for IGF-I and GHBP over 72 hours following GH administration. OM had lower peak IGF-I levels (323 ± 38 vs. 497 ± 85 μg/l, p = 0.0015) and a lower IGF-I response to GH (ΔIGF-I: 187 ± 33 vs. 293 ± 57 μg/l, p = 0.0085) than YM. OFE had lower basal IGF-I (63 ± 11 vs. 133 ± 19 μg/1, p= 0.0046), peak IGF-I (174 ± 28 vs. 400 ± 40 μg/l, p = 0.0015), and ΔIGF-I (111 ± 21 vs. 268 ± 27 μg/l, p = 0.0085) than OFN. IGFBP-3 levels were unchanged 24 hours after GH administration. GHBP levels fell transiently in all subjects by an average of 22.9 ± 1.7{\%}, with no differences among the groups. There was no correlation between IGF-I response and basal GHBP levels (r = 0.169, p > 0.35). We conclude that (1) a single subcutaneous dose of GH is a convenient and direct method for assessing responsiveness to GH, (2) aging in males and oral estrogen therapy in postmenopausal women are accompanied by resistance to GH, (3) GH administration acutely lowers circulating GHBP, and (4) the level of circulating GHBP does not predict the IGF-I response to GH.",
keywords = "aging, estrogen, growth hormone, growth hormone-binding protein, IGF-binding protein 3, insulin-like growth factor I",
author = "Steven Lieberman and Mitchell, {A. M.} and R. Marcus and Hintz, {R. L.} and Hoffman, {A. R.}",
year = "1994",
language = "English (US)",
volume = "26",
pages = "229--233",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "5",

}

TY - JOUR

T1 - The insulin-like growth factor I generation test

T2 - Resistance to growth hormone with aging and estrogen replacement therapy

AU - Lieberman, Steven

AU - Mitchell, A. M.

AU - Marcus, R.

AU - Hintz, R. L.

AU - Hoffman, A. R.

PY - 1994

Y1 - 1994

N2 - Circulating IGF-I is primarily regulated by growth hormone, but other factors such as nutritional status may also influence IGF-I secretion. The effects of age, gender, and estrogen replacement on responsiveness of serum IGF-I to GH administration have not been directly studied. The high affinity circulating GH-binding protein (GHBP) has the same structure as the extracellular domain of the GH receptor and may reflect the sensitivity to GH in humans. To examine these issues, we employed an IGF-I generation test in which a single dose of GH (0.1 mg/kg SQ) was administered to 31 healthy adults comprising five groups: young (20-29 years) males (YM), young females in the follicular phase of the menstrual cycle (YF), older (60-69 years) males (OM), older females not on estrogen replacement (OFN), and older females on oral estrogen replacement (OFE). Blood was sampled for IGF-I and GHBP over 72 hours following GH administration. OM had lower peak IGF-I levels (323 ± 38 vs. 497 ± 85 μg/l, p = 0.0015) and a lower IGF-I response to GH (ΔIGF-I: 187 ± 33 vs. 293 ± 57 μg/l, p = 0.0085) than YM. OFE had lower basal IGF-I (63 ± 11 vs. 133 ± 19 μg/1, p= 0.0046), peak IGF-I (174 ± 28 vs. 400 ± 40 μg/l, p = 0.0015), and ΔIGF-I (111 ± 21 vs. 268 ± 27 μg/l, p = 0.0085) than OFN. IGFBP-3 levels were unchanged 24 hours after GH administration. GHBP levels fell transiently in all subjects by an average of 22.9 ± 1.7%, with no differences among the groups. There was no correlation between IGF-I response and basal GHBP levels (r = 0.169, p > 0.35). We conclude that (1) a single subcutaneous dose of GH is a convenient and direct method for assessing responsiveness to GH, (2) aging in males and oral estrogen therapy in postmenopausal women are accompanied by resistance to GH, (3) GH administration acutely lowers circulating GHBP, and (4) the level of circulating GHBP does not predict the IGF-I response to GH.

AB - Circulating IGF-I is primarily regulated by growth hormone, but other factors such as nutritional status may also influence IGF-I secretion. The effects of age, gender, and estrogen replacement on responsiveness of serum IGF-I to GH administration have not been directly studied. The high affinity circulating GH-binding protein (GHBP) has the same structure as the extracellular domain of the GH receptor and may reflect the sensitivity to GH in humans. To examine these issues, we employed an IGF-I generation test in which a single dose of GH (0.1 mg/kg SQ) was administered to 31 healthy adults comprising five groups: young (20-29 years) males (YM), young females in the follicular phase of the menstrual cycle (YF), older (60-69 years) males (OM), older females not on estrogen replacement (OFN), and older females on oral estrogen replacement (OFE). Blood was sampled for IGF-I and GHBP over 72 hours following GH administration. OM had lower peak IGF-I levels (323 ± 38 vs. 497 ± 85 μg/l, p = 0.0015) and a lower IGF-I response to GH (ΔIGF-I: 187 ± 33 vs. 293 ± 57 μg/l, p = 0.0085) than YM. OFE had lower basal IGF-I (63 ± 11 vs. 133 ± 19 μg/1, p= 0.0046), peak IGF-I (174 ± 28 vs. 400 ± 40 μg/l, p = 0.0015), and ΔIGF-I (111 ± 21 vs. 268 ± 27 μg/l, p = 0.0085) than OFN. IGFBP-3 levels were unchanged 24 hours after GH administration. GHBP levels fell transiently in all subjects by an average of 22.9 ± 1.7%, with no differences among the groups. There was no correlation between IGF-I response and basal GHBP levels (r = 0.169, p > 0.35). We conclude that (1) a single subcutaneous dose of GH is a convenient and direct method for assessing responsiveness to GH, (2) aging in males and oral estrogen therapy in postmenopausal women are accompanied by resistance to GH, (3) GH administration acutely lowers circulating GHBP, and (4) the level of circulating GHBP does not predict the IGF-I response to GH.

KW - aging

KW - estrogen

KW - growth hormone

KW - growth hormone-binding protein

KW - IGF-binding protein 3

KW - insulin-like growth factor I

UR - http://www.scopus.com/inward/record.url?scp=0028359763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028359763&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 229

EP - 233

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 5

ER -